Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic High Grade Fallopian Tube Serous Adenocarcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Primary Peritoneal Serous Adenocarcinoma|Metastatic Triple-Negative Breast Carcinoma|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Breast Carcinoma|Recurrent High Grade Fallopian Tube Serous Adenocarcinoma|Recurrent High Grade Ovarian Serous Adenocarcinoma|Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma|Recurrent Triple-Negative Breast Carcinoma|Refractory Fallopian Tube Serous Adenocarcinoma|Refractory Ovarian Serous Adenocarcinoma|Refractory Primary Peritoneal Serous Adenocarcinoma|Refractory Triple-Negative Breast Carcinoma|Unresectable High Grade Fallopian Tube Serous Adenocarcinoma|Unresectable Malignant Solid Neoplasm|Unresectable Primary Peritoneal Serous Adenocarcinoma
Interventions: DRUG: Olaparib|DRUG: Onalespib
Sponsor: National Cancer Institute (NCI)